Participants 106 157 3
cytomegalovirus disease after renal transplantation
Participants 455 673 12
A total of 38 patients was randomized to 3-month treatment with either oral ganciclovir (1 g t.i.d., n=14, GAN group) or oral valacyclovir (2 g q.i.d., n=12, VAL group). A third group (C, n=12) received no prophylaxis.
Participants 885 946 3
Thirty-six out of 38 (94.7%) recipients were CMV-seropositive
Participants 993 1060 4
13 episodes of CMV disease in eight (66.7%) patients of the C group
